Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Regadenoson (CV Therapeutics/Astellas).

Holger Eggbrecht1, Mario Gössl

  • 1Department of Cardiology, University of Duisburg-Essen, Germany. holger.eggebrecht@uni-essen.de

Current Opinion in Investigational Drugs (London, England : 2000)
|March 25, 2006
PubMed
Summary

Regadenoson, an adenosine A2A receptor agonist, is being developed for cardiac perfusion imaging to detect coronary artery disease. Early phase III clinical trial results show promise for this pharmacological imaging agent.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

10-Year Randomized Outcomes of Transcatheter or Surgical Aortic Valve Replacement in Intermediate-Risk Aortic Stenosis.

Journal of the American College of Cardiology·2026
Same author

Redo-TAVR Leaflet Modification: When Mechanics Trump Technique and Why Lifetime Strategy Begins With the First Valve.

JACC. Cardiovascular interventions·2026
Same author

30-Day Outcomes of a Single-Stage Transfemoral Mitral Valve Replacement System in Severe Mitral Valve Disease.

JACC. Cardiovascular interventions·2026
Same author

Temporal change in patients with mitral annular calcification after successful aortic valve intervention.

Cardiovascular revascularization medicine : including molecular interventions·2026
Same author

Transcatheter Mitral Valve Replacement for Severe Mitral Annular Calcification: Primary Outcomes From the SUMMIT-MAC Study.

Journal of the American College of Cardiology·2025
Same author

Three-Year Outcomes of Second Bioprosthesis After Early Surgical Aortic Bioprosthetic Failure.

JACC. Advances·2025

Area of Science:

  • Cardiovascular medicine
  • Pharmacological imaging
  • Radiology

Background:

  • Coronary artery disease (CAD) diagnosis relies on accurate cardiac perfusion studies.
  • Pharmacological agents are used to induce hyperemia in patients unable to undergo exercise stress testing.

Purpose of the Study:

  • To evaluate regadenoson, an adenosine A2A receptor agonist, as an intravenous pharmacological imaging agent.
  • To assess the potential of regadenoson in detecting coronary artery disease through cardiac perfusion imaging.

Main Methods:

  • Regadenoson is being codeveloped by CV Therapeutics and Astellas.
  • The study involves phase III clinical trials for intravenous administration.
  • Cardiac perfusion imaging is utilized to assess myocardial blood flow.

Main Results:

  • Positive results from the first of two phase III clinical studies were reported in August 2005.
  • The data suggests regadenoson's efficacy as an adjunctive imaging agent.

Conclusions:

  • Regadenoson shows potential as a safe and effective pharmacological tool for cardiac perfusion imaging.
  • Further clinical studies are ongoing to confirm its role in diagnosing coronary artery disease.

Related Experiment Videos